Can-Fite Biopharma Has Received A Notice Of Allowance For A US Patent Titled "AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT (FOR THE TREATMENT OF OBESITY)"

Benzinga12/13 04:58

Bears Are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now

Zacks 12/09 22:05

Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital

Dow Jones12/05 20:16

Can-Fite Biopharma Price Target Maintained With a $10.00/Share by D. Boral Capital

Dow Jones12/05 20:16

8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Can-Fite's Namodenoson Drug

GlobeNewswire12/04 20:00

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire11/22 22:00